Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

- PMLiVE

Seres’ microbiome-based therapy hits the mark in phase 3

Drug reduced C.difficile infection recurrence

Combating Coronavirus Through Reversing Diabetes

The Diabetes Reversal Company has developed a pioneering programme based on sustainable weight loss, evidence-based lifestyle change and one-to-one clinical support to reduce and reverse the effects of Type 2...

Onyx Health

- PMLiVE

Delivering safe and effective clinical trials during the COVID-19 pandemic

By Jorg Taubel

- PMLiVE

Eli Lilly, Innovent showcase Tyvyt data in first-line NSCLC

Detailed phase 3 results presented at the virtual World Conference on Lung Cancer

- PMLiVE

Biogen’s highly-anticipated Alzheimer’s drug wins FDA fast-track

Drug could become first treatment to reduce clinical decline in Alzheimer's

Roche Basel Switzerland

Roche scores FDA approval for SMA drug risdiplam, now named Evrysdi

Drug poised to challenge rivals Spinraza and Zolgensma

- PMLiVE

AI: the smart money is on the smart thinking

Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials

- PMLiVE

The blurred lines between sepsis and COVID-19

This week, the UK Sepsis Trust (UKST) launched a new health communications campaign to raise awareness of the relationship between COVID-19 and sepsis, and to offer patient support to those...

11 London

Porterhouse Medical Group

Porterhouse Medical Group joins imc group

Agency will be a key addition to imc's growing network of international offices

- PMLiVE

Bristol-Myers Squibb’s revenues rise on Celgene acquisition

Sales of immunotherapy Opdivo decreased due to COVID-19 impact

- PMLiVE

Tecentriq combo fails in advanced triple negative breast cancer

Tecentriq plus paclitaxel failed to improve progression-free survival

- PMLiVE

Biogen pays Denali $1bn upfront for Parkinson’s disease programme

Deal includes portfolio of small molecule LRRK2 inhibitors

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links